MedWatch

Pharmaceutical watchdog bans Novo ad following new Sanofi complaint

Novo Nordisk did not make sufficient changes to the advertisement that the Ethical Committee for the Pharmaceutical Industry (ENLI) recently determined to be misleading and unfair to the competitor Sanofi.

Foto: Colourbox

A Novo Nordisk advertisement that compares the company's drug Tresiba to Sanofi's drug Toujei still violates the industry's ethical guidelines, despite adjustments. The Ethical Committee for the Pharmaceutical Industry (ENLI) had already preapproved the advertisement, however, that ruling has since been withdrawn.

The decision was made by the Appeal Board under ENLI, and it settled an appeal made by Sanofi, the French pharmaceutical giant and Novo Nordisk's arch rival.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Nye insulintilskud bekymrer Diabetesforeningen

Diabetesforeningen er utilfredse med Medicintilskudsnævnets indstilling til en revurdering af tilskud for diabetesmidler, som patientforeningen anser som en spareøvelse uden hensyntagen til patienterne.

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier